Renal Department, St James's University Hospital, Lincoln Wing, Beckett Street LS9 7TF, UK.
Ann Clin Biochem. 2010 Jan;47(Pt 1):4-7. doi: 10.1258/acb.2009.009249.
Over recent years, there has been welcome increased interest in acute kidney injury (AKI) and its association with patient outcome. The term AKI has replaced the term acute renal failure (ARF) and encompasses all types of ARF. New definitions and staging systems for AKI have been proposed, which have stimulated a multitude of different studies to evaluate their clinical utility. These recent advances need to be communicated to the wider health care community so that we are using a shared nomenclature. In 2009 the National Confidential Enquiry into Patient Outcome and Death AKI study ('Adding Insult to Injury') announced its findings and recommendations. The report recommended that the detection of AKI and its management should be improved. These recommendations along with the adoption of the new staging systems will potentially have an impact on clinical biochemistry departments and exert an increased demand on resources. Running in parallel with these initiatives is the quest to discover novel biomarkers to detect AKI, the development and introduction of which will require laboratory support.
近年来,人们对急性肾损伤 (AKI) 及其与患者预后的关系越来越感兴趣。AKI 这一术语已经取代了急性肾衰竭 (ARF),涵盖了所有类型的 ARF。新的 AKI 定义和分期系统已经提出,这激发了大量不同的研究来评估它们的临床实用性。这些最新进展需要向更广泛的医疗保健界传播,以便我们使用共享的命名法。2009 年,国家患者结局和死亡急性肾损伤调查 ('雪上加霜') 公布了其调查结果和建议。报告建议应改善 AKI 的检测和管理。这些建议以及新分期系统的采用将对临床生化科产生影响,并增加对资源的需求。与这些举措并行的是发现新型生物标志物来检测 AKI 的探索,这需要实验室的支持。